6,613 reports of this reaction
3.2% of all PALBOCICLIB reports
#6 most reported adverse reaction
NEUTROPENIA is the #6 most commonly reported adverse reaction for PALBOCICLIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 6,613 FDA adverse event reports linking PALBOCICLIB to NEUTROPENIA. This represents approximately 3.2% of all 205,909 adverse event reports for this drug.
PALBOCICLIB has an overall safety score of 78 out of 100. Patients taking PALBOCICLIB who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among PALBOCICLIB users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for PALBOCICLIB:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 6,613 FDA reports for PALBOCICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.2% of all adverse event reports for PALBOCICLIB, making it a notable side effect.
If you experience neutropenia while taking PALBOCICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.